Cannabidiol inhibits angiogenesis by multiple mechanisms

British Journal of Pharmacology

Volumn 167, Issue 6, 2012, Pages 1218-1231

  Solinas, M ^a   Massi, P ^b   Cantelmo, A R ^c   Cattaneo, M G ^b   Cammarota, R ^c   Bartolini, D ^c   Cinquina, V ^a   Valenti, M ^a   Vicentini, L M ^b   Noonan, D M ^a   Albini, A ^c   Parolaro, D ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

angiogenesis; cannabidiol; HUVEC; invasion; migration; tube formation

Indexed keywords

CANNABIDIOL; GELATINASE A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOSTASIS; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPHEROID CELL; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; CANNABIDIOL; CELL MOVEMENT; HEPARIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867803387     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02050.x     Document Type: Article

References (89)

1. Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P, et al,. (1994). Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS 8: 1237-1244.
2. Albini A, Brigati C, Ventura A, Lorusso G, Pinter M, Morini M, et al,. (2009). Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J Transl Med 14: 7-5.
3. Albini A, Indraccolo S, Noonan DM, Pfeffer U, (2010). Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs. Clin Exp Metastasis 27: 419-439.
4. Alexander A, Smith PF, Rosengren RJ, (2009). Cannabinoids in the treatment of cancer. Cancer Lett 285: 6-12.
5. Alexander CM, Howard EW, Bissell MJ, Werb Z, (1996). Rescue of mammary epithelial apoptosis and entactin degradation by a tissue inhibitor of metalloproteinase-1 transgene. J Cell Biol 135: 1669-1677.
6. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
7. Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F, et al,. (2012). Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med DOI: 10.1007/s00109-011- 0856-x [Epub ahead of print].
8. Bagnato A, Spinella F, Rosanà L, (2008). The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol 86: 473-484.
9. Bátkai S, Járai Z, Wagner JA, Goparaju SK, Varga K, Liu J, et al,. (2001). Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7: 827-832.
10. Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, et al,. (2002). Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 16: 267-269.
11. Benelli R, Albini A, Noonan D, (2003). Neutrophils and angiogenesis: potential initiators of the angiogenic cascade. In:, Cassatella MA, (ed.). The Neutrophil: An Emerging Regulator of Inflammatory and Immune Response. Karger: Basel, pp. 167-181.
12. Bertaux B, Hornebeck W, Eisen AZ, Dubertret L, (1991). Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 97: 679-685.
13. Blázquez C, Casanova ML, Planas A, Gõmez del Pulgar T, Villanueva C, Fernández-Aceñero MJ, et al,. (2003). Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17: 529-531.
14. Blázquez C, González-Feria L, Alvarez L, Haro A, Casanova ML, Guzmán M, (2004). Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64: 5617-5623.
15. Blázquez C, Carracedo A, Barrado L, Real PJ, Fernández-Luna JL, Velasco G, et al,. (2006). Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 20: 2633-2635.
16. Cantelmo AR, Cammarota R, Noonan DM, Focaccetti C, Comoglio PM, Prat M, et al,. (2010). Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth. Oncogene 29: 5286-5298.
17. Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW, et al,. (2003). Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111: 43-50.
18. Cattaneo MG, Chini B, Vicentini LM, (2008). Oxytocin stimulates migration and invasion in human endothelial cells. Br J Pharmacol 153: 728-736.
19. Cattaneo MG, Lucci G, Vicentini LM, (2009). Oxytocin stimulates in vitro angiogenesis via a Pyk-2/Src-dependent mechanism. Exp Cell Res 315: 3210-3219.
20. Chung AS, Lee J, Ferrara N, (2010). Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10: 505-514.
21. Curry FR, Glass CA, (2006). TRP channels and the regulation of vascular permeability: new insights from the lung microvasculature. Circ Res 99: 915-917.
22. De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, et al,. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163: 1479-1494.
23. Fassina G, Venè R, Morini M, Minghelli S, Benelli R, Noonan DM, et al,. (2004). Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res 10: 4865-4873.
24. Ferrari N, Tosetti F, De Flora S, Donatelli F, Noonan DM, Albini A, (2010). Diet-derived phytochemicals: from cancer chemoprevention to cardio-oncological prevention. Curr Drug Targets 12: 1909-1924.
25. Fiorio Pla A, Avanzato D, Munaron L, Ambudkar IS, (2012). Ion channels and transporters in cancer. 6. Vascularizing the tumor: TRP channels as molecular targets. Am J Physiol Cell Physiol 302: C9-C15.
26. Flygare J, Sander B, (2008). The endocannabinoid system in cancer-potential therapeutic target? Semin Cancer Biol 18: 176-189.
27. Folkman J, (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
28. Folkman J, (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
29. Freimuth N, Ramer R, Hinz B, (2010). Antitumorigenic effects of cannabinoids beyond apoptosis. J Pharmacol Exp Ther 332: 336-344.
30. Gertsch J, Pertwee RG, Di Marzo V, (2010). Phytocannabinoids beyond the Cannabis plant-do they exist? Br J Pharmacol 160: 523-529.
31. Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, et al,. (2004). Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 132: 87-92.
32. Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Créme E, et al,. (2005). Tissue inhibitor of metalloproteinase-1 is an independent predictor of prognosis in patients with non-small cell lung carcinoma who undergo resection with curative intent. Cancer 103: 1676-1684.
33. Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, Kleinman HK, (1989). Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58: 933-943.
34. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, et al,. (1998). In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102: 2002-2010.
35. Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler-Stevenson M, Stetler-Stevenson WG, (2001). Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects of tumor growth and angiogenesis. Am J Pathol 158: 1207-1215.
36. Guindon J, Hohmann AG, (2011). The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol 163: 1447-1463.
37. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K, (1992). Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298: 29-32.
38. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
39. Jaffe EA, Nachman RL, Becker CG, Minick CR, (1973). Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunological criteria. J Clin Invest 52: 2745-2756.
40. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, et al,. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 96: 14136-14141.
41. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, et al,. (2005). Matrix metalloproteinases in carcinoma of unknown primary. Cancer 104: 2282-2287.
42. Kesisis G, Broxterman H, Giaccone G, (2007). Angiogenesis inhibitors. Drug selectivity and target specificity. Curr Pharm Des 13: 2795-2809.
43. Korff T, Augustin HG, (1998). Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol 143: 1341-1352.
44. Korff T, Augustin HG, (1999). Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J Cell Sci 112: 3249-3258.
45. Kwan HY, Huang Y, Yao X, (2007). TRP channels in endothelial function and dysfunction. Biochim Biophys Acta 1772: 907-914.
46. Lafleur MA, Handsley MM, Knäuper V, Murphy G, Edwards DR, (2002). Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type matrix metalloproteinases (MT-MMPs). J Cell Sci 115: 3427-3428.
47. Lai Y, Shen Y, Liu XH, Zhang Y, Zeng Y, Liu YF, (2011). Interleukin-8 induces the endothelial cell migration through the activation of phosphoinositide 3-kinase-Rac1/RhoA pathway. Int J Biol Sci 7: 782-791.
48. Li G, Fridman R, Kim HR, (1999). Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 59: 6267-6275.
49. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, et al,. (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318: 1375-1387.
50. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A, et al,. (2000). Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346: 835-840.
51. Lorusso G, Vannini N, Sogno I, Generoso L, Garbisa S, Noonan DM, et al,. (2009). Mechanisms of hyperforin as an anti-angiogenic angioprevention agent. Eur J Cancer 45: 1474-1484.
52. Marcu JP, Christian RT, Lau D, Zielinski AJ, Horowitz MP, Lee J, et al,. (2010). Cannabidiol enhances the inhibitory effects of delta9- tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 9: 180-189.
53. Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D, (2004). Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308: 838-845.
54. Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D, (2006). The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci 63: 2057-2066.
55. Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E, et al,. (2008). 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 104: 1091-1100.
56. McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY, (2007). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 6: 2921-2927.
57. McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, et al,. (2011). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 129: 37-47.
58. McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, et al,. (2002). Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100: 627-634.
59. McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M, (2006). Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol 70: 897-908.
60. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
61. Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, et al,. (1997). Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 76: 531-536.
62. Mo FM, Offertáler L, Kunos G, (2004). Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur J Pharmacol 489: 21-27.
63. Nasser JA, Falavigna A, Ferraz F, Duigou G, Bruce J, (2006). Transcription analysis of TIMP-1 and NM23-H1 genes in glioma cell invasion. Arq Neuropsiquiatr 64: 774-780.
64. Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A, (2008). Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev 27: 31-40.
65. Noonan DM, Ventura A, Bruno A, Pagani A, Albini A, (2011a). The angiogenic switch: role of immune cells. In:, Wang E, Marincola F, (eds). Immunologic Signatures of Rejection. Springer: New York, pp. 57-75.
66. Noonan DM, Sogno I, Albini A, (2011b). Plants and plant-derived products as cancer chemopreventive agents. In:, Bagetta G, Cosentino M, Corasaniti MT, Sakurada S, (eds). Herbal Medicines: Development and Validation of Plant-Derived Medicines for Human Health. CRC Press Inc: Boca Raton, FL, pp. 285-306.
67. O'Sullivan SE, Kendall DA, (2010). Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 215: 611-616.
68. O'Sullivan SE, Sun Y, Bennett AJ, Randall MD, Kendall DA, (2009). Time-dependent vascular actions of cannabidiol in the rat aorta. Eur J Pharmacol 612: 61-68.
69. Pisanti S, Borselli C, Oliviero O, Laezza C, Gazzerro P, Bifulco M, (2007). Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol 211: 495-503.
70. Pisanti S, Picardi P, Prota L, Proto MC, Laezza C, McGuire PG, et al,. (2011). Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood 117: 5541-5550.
71. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M, (2003). Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17: 1771-1773.
72. Preet A, Ganju RK, Groopman JE, (2008). Delta9-tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 27: 339-346.
73. Qiu J, Wang G, Hu J, Peng Q, Zheng Y, (2011). Id1-induced inhibition of p53 facilitates endothelial cell migration and tube formation by regulating the expression of beta1-integrin. Mol Cell Biochem 357: 125-133.
74. Rabquer BJ, Tsou PS, Hou Y, Thirunavukkarasu E, Haines GK 3rd, Impens AJ, et al,. (2011). Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther 13: R18.
75. Raghu H, Lakka SS, Gondi CS, Mohanam S, Dinh DH, Gujrati M, et al,. (2010). Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines. PLoS ONE 5: e12458.
76. Ramer R, Merkord J, Rohde H, Hinz B, (2010a). Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol 79: 955-966.
77. Ramer R, Rohde A, Merkord J, Rohde H, Hinz B, (2010b). Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. Pharm Res 27: 2162-2174.
78. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O, (1997). High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 3: 1623-1628.
79. Russo EB, (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163: 1344-1364.
80. Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, et al,. (2004). Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 10: 2289-2298.
81. Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A, (2011). Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 10: 1161-1172.
82. Torres S, Lorente M, Rodríguez-Fornés F, Hernández-Tiedra S, Salazar M, García-Taboada E, et al,. (2011). A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10: 90-103.
83. Ulisse S, Baldini E, Sorrenti S, D'Armiento M, (2009). The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 9: 32-71.
84. Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D, (2005). Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144: 1032-1036.
85. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G, (1997). Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390: 518-521.
86. Yokoyama Y, Xin B, Shigeto T, Mizunuma H, (2011). Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. J Cancer Res Clin Oncol 137: 1219-1228.
87. Yoshiji J, Harris SR, Raso E, Gomez DE, Lindsay CK, Shibuya M, et al,. (1998). Mammary carcinoma cells overexpressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 75: 81-87.
88. Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W, Guillem JG, (1995). Elevated tissue inhibitor of metalloproteinase I RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1: 899-906.
89. Zhuge X, Murayama T, Arai H, Yamauchi R, Tanaka M, Shimaoka T, et al,. (2005). CXCL16 is a novel angiogenic factor for human umbilical vein endothelial cells. Biochem Biophys Res Commun 331: 1295-1300.